Slingshot members are tracking this event:
Phase 3 GAUSS-3 Trial Of Repatha (Evolocumab) In Statin-Intolerant Patients With High Cholesterol Meets Co-Primary Endpoints of LDL Cholesterol Reduction
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
In the GAUSS-3 trial there were no new safety findings. The most common adverse events that occurred in greater than 5 percent of patients in the Repatha group were myalgia, nasopharyngitis, muscle spasms, arthralgia, pain in extremity, fatigue, headache and back pain.
Slingshot Insights Explained
Feb 04, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Trial, Gauss-3, Evolocumab, Statin-intolerant Patients, High Cholesterol, Ldl Cholesterol Reduction, Primary Endpoints, Repatha, Low-density Lipoprotein Cholesterol, Statins